CTLA4 and neoplasm: Mutation neoantigens are critical for tumor control: T cells recognize mutant peptides bound to MHC alleles on tumor cells both in mice and humans (1) and tumor mutational burden (TMB) predicts tumor response to anti-CTLA4 (2) and anti-PD1 treatment (3).